Format

Send to

Choose Destination
Biomed Res Int. 2014;2014:919474. doi: 10.1155/2014/919474. Epub 2014 Sep 11.

Highlight on advances in nontuberculous mycobacterial disease in North America.

Author information

1
Section of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine M/C 719, University of Illinois at Chicago, 840 S. Wood Street, Chicago, IL 60612-7323, USA.
2
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
3
Department of Health, University of Louisville, Louisville, KY 40202, USA.
4
Department of Biological Science, University of Virginia Tech, Blacksburg, VA 24061, USA.

Abstract

Nontuberculous mycobacteria (NTM) are ubiquitous in the environment and exist as an important cause of pulmonary infections in humans. Pulmonary involvement is the most common disease manifestation of NTM and the incidence of NTM is growing in North America. Susceptibility to NTM infection is incompletely understood; therefore preventative tools are not well defined. Treatment of pulmonary nontuberculous mycobacterial (NTM) infection is difficult and entails multiple antibiotics and an extended treatment course. Also, there is a considerable variation in treatment management that should be considered before initiating treatment. We highlight the new findings in the epidemiology diagnosis and treatment of mycobacterial infections. We debate new advances regarding NTM infection in cystic fibrosis patients and solid organ transplant recipients. Finally, we introduce a new epidemiologic model for NTM disease based on virulence-exposure-host factors.

PMID:
25574470
PMCID:
PMC4177089
DOI:
10.1155/2014/919474
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center